Fig. 6From: Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancerEffect of minocycline WP on immunohistological changes of EGFR after afatinib administration. a afatinib administration only, b treatment with minocycline WP from the 10th day after administration of afatinib, c treatment with minocycline WP from the 5th day after administration of afatinib, and d pretreatment with minocycline WP before administration of afatinib for 3 daysBack to article page